血浆半乳糖凝集素-3可被视为一种无创标志物，用于预测新分型的慢加急性肝衰竭（ACLF）患者的预后。
Plasma galectin-3 can be considered as a non-invasive marker to predict the prognosis of ACLF patients with new typing.
作者信息
Bai Li, Lu Wang, Yang Qi, Liu Xiaoxuan, Chen Yu, Duan Zhongping
机构信息
Fourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, No. 8, Xi Tou Tiao, Youanmenwai Street, Fengtai District, Beijing, 100069, China.
Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, 100069, China.
出版信息
Sci Rep. 2025 Jan 31;15(1):3916. doi: 10.1038/s41598-025-87557-9.
Very recently, we creatively put forward a new classification for ACLF patients, which lays the foundation for the establishment of prognostic model that can accurately predict the prognosis of ACLF patients. Herein, we found: galectin-3 levels were higher in type A ACLF patients compared to those of type B patients; galectin-3 expression was closely correlated with TBil, PTA/INR and MELD; galectin-3 is an independent predictive factor for rapid progression in ACLF, and exhibited superior predictive value for the prognosis of type A ACLF patients than MELD score; and the survival rate was remarkably higher in ACLF patients with lower galectin-3 expression. Collectively, galectin-3 can be considered as a non-invasive biomarker to predict the prognosis of ACLF patients with new typing. Our findings help advance the time window of prognosis prediction for type A and type B ACLF patients from 4 weeks to the baseline, thereby identifying ACLF patients who really need liver transplantation earlier and improving the survival of ACLF patients.
最近，我们创造性地提出了一种针对慢加急性肝衰竭（ACLF）患者的新分类方法，这为建立能够准确预测ACLF患者预后的预测模型奠定了基础。在此，我们发现：与B型患者相比，A型ACLF患者的半乳糖凝集素-3水平更高；半乳糖凝集素-3表达与总胆红素（TBil）、凝血酶原活动度/国际标准化比值（PTA/INR）及终末期肝病模型（MELD）密切相关；半乳糖凝集素-3是ACLF快速进展的独立预测因素，并且对于A型ACLF患者的预后，其预测价值优于MELD评分；半乳糖凝集素-3表达较低的ACLF患者生存率显著更高。总体而言，半乳糖凝集素-3可被视为预测新分型ACLF患者预后的一种非侵入性生物标志物。我们的研究结果有助于将A型和B型ACLF患者预后预测的时间窗从4周提前至基线期，从而更早地识别真正需要肝移植的ACLF患者，并提高ACLF患者的生存率。
Zotero 插件